Preparation and in vitro/in vivo evaluation of a clonidine hydrochloride drug–resin suspension as a sustained-release formulation

Hongfei Liu,Xiaoya Xie,Chao Chen,Caleb Kesse Firempong,Yingshu Feng,Limin Zhao,Xuezhi Yin
DOI: https://doi.org/10.1080/03639045.2021.1890110
IF: 3.727
2021-03-04
Drug Development and Industrial Pharmacy
Abstract:<span>The purpose of the present study was to prepare a clonidine hydrochloride (CH) sustained-release suspension.The processes involved in the drug formulation included drug loading, impregnating, and suspension preparation. Clonidine hydrochloride drug–resin complexes (CH-DRC) were prepared using the bath method and the CH-DRC impregnated before the microencapsulation process. Based on the bottom spray fluidized bed coating method, the CH microencapsulated drug–resin complexes (CH-MC) were also prepared using Surelease<sup>®</sup> (the suspension of ethyl cellulose aqueous dispersion) as the coating material. The effects of coating (process/formulation) on the <i>in vitro</i> release of coating microcapsule were evaluated via single factor investigation and orthogonal design optimization. The CH-MC with optimized formulation was further dispersed in a suitable medium to obtain a sustained-release suspension. Rats were given commercial CH ordinary tablets and the CH sustained-release suspension via intragastric administration. The plasma concentration–time curve and related pharmacokinetic parameters were investigated using the non-compartment model.The <i>T</i><sub>max</sub> of the CH sustained-release suspension was delayed from 2 h to 5 h compared with the CH ordinary tablets. Similarly, the <i>C</i><sub>max</sub> was reduced from 32.138 µg·mL<sup>−1</sup> to 18.150 µg·mL<sup>−1</sup> with the concentration–time curve being more gentle compared with the commercially CH ordinary tablets. After oral administration, the relative bioavailability of CH sustained-release suspension (AUC<sub>0–24</sub> of 137.703 µg·h·mL<sup>−1</sup>) to its CH ordinary tablets (AUC<sub>0–24</sub> of 123.337 µg·h·mL<sup>−1</sup>) was 111.65%.The findings showed that the CH sustained-release suspension for oral administration was successfully formulated.</span>
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?